Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)

NCT01807234 Phase 4 COMPLETED Results posted

The investigators propose to test the efficacy of ketorolac nasal spray versus sumatriptan nasal spray versus placebo for acute abortive therapy of migraine head pain as well as for migraine associated symptoms including nausea and allodynia.

Details

Lead sponsor	Johns Hopkins University
Phase	Phase 4
Status	COMPLETED
Enrolment	72
Start date	2013-02
Completion	2014-12

Conditions

• Migraines

Interventions

• Ketorolac
• Sumatriptan
• Placebo

Primary outcomes

• 2- Hour Pain Relief — 2 hours
  The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe)

Countries

United States